These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 18030070

  • 1. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
    Di Napoli P, Di Giovanni P, Gaeta MA, Taccardi AA, Barsotti A.
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):585-9. PubMed ID: 18030070
    [Abstract] [Full Text] [Related]

  • 2. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy.
    Marazzi G, Gebara O, Vitale C, Caminiti G, Wajngarten M, Volterrani M, Ramires JA, Rosano G, Fini M.
    Adv Ther; 2009 Apr; 26(4):455-61. PubMed ID: 19396409
    [Abstract] [Full Text] [Related]

  • 3. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy.
    Di Napoli P, Di Giovanni P, Gaeta MA, D'Apolito G, Barsotti A.
    Am Heart J; 2007 Sep; 154(3):602.e1-5. PubMed ID: 17719313
    [Abstract] [Full Text] [Related]

  • 4. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
    Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A.
    J Am Coll Cardiol; 2006 Sep 05; 48(5):992-8. PubMed ID: 16949492
    [Abstract] [Full Text] [Related]

  • 5. Role of trimetazidine in management of ischemic cardiomyopathy.
    Bertomeu-Gonzalez V, Bouzas-Mosquera A, Kaski JC.
    Am J Cardiol; 2006 Sep 04; 98(5A):19J-24J. PubMed ID: 16931202
    [Abstract] [Full Text] [Related]

  • 6. [The effects of trimetazidine on left ventricular function and physical exercise tolerance in patients with ischemic cardiomyopathy].
    Sisakian AS, Torgomian AL, Barkhudarian AL.
    Klin Med (Mosk); 2006 Sep 04; 84(10):55-8. PubMed ID: 17201276
    [Abstract] [Full Text] [Related]

  • 7. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation.
    Belardinelli R, Lacalaprice F, Faccenda E, Volpe L.
    Eur J Cardiovasc Prev Rehabil; 2008 Oct 04; 15(5):533-40. PubMed ID: 18797405
    [Abstract] [Full Text] [Related]

  • 8. Differences in management and outcome of ischemic and non-ischemic cardiomyopathy.
    Ng AC, Sindone AP, Wong HS, Freedman SB.
    Int J Cardiol; 2008 Sep 26; 129(2):198-204. PubMed ID: 17706807
    [Abstract] [Full Text] [Related]

  • 9. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.
    Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, Volterrani M, Rosano GM.
    Eur Heart J; 2004 Oct 26; 25(20):1814-21. PubMed ID: 15474696
    [Abstract] [Full Text] [Related]

  • 10. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
    Belardinelli R, Cianci G, Gigli M, Mazzanti M, Lacalaprice F.
    J Cardiovasc Pharmacol; 2008 Jun 26; 51(6):611-5. PubMed ID: 18574390
    [Abstract] [Full Text] [Related]

  • 11. Trimetazidine shortens QTc interval in patients with ischemic heart failure.
    Zemljic G, Bunc M, Vrtovec B.
    J Cardiovasc Pharmacol Ther; 2010 Mar 26; 15(1):31-6. PubMed ID: 19966175
    [Abstract] [Full Text] [Related]

  • 12. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
    Belardinelli R.
    Rev Port Cardiol; 2000 Nov 26; 19 Suppl 5():V35-9. PubMed ID: 11206102
    [Abstract] [Full Text] [Related]

  • 13. [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].
    Fedorova TA, Il'ina IuV, Sotnikova TI, Rybakova MK.
    Klin Med (Mosk); 2004 Nov 26; 82(11):15-20. PubMed ID: 15656392
    [Abstract] [Full Text] [Related]

  • 14. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
    Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, Calori G, Lopaschuk GD, Margonato A.
    Am Heart J; 2003 Nov 26; 146(5):E18. PubMed ID: 14597947
    [Abstract] [Full Text] [Related]

  • 15. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure.
    Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, Scifo P, Calori G, Del Maschio A, Margonato A.
    Eur Heart J; 2006 Apr 26; 27(8):942-8. PubMed ID: 16510466
    [Abstract] [Full Text] [Related]

  • 16. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
    Fragasso G, Salerno A, Lattuada G, Cuko A, Calori G, Scollo A, Ragogna F, Arioli F, Bassanelli G, Spoladore R, Luzi L, Margonato A, Perseghin G.
    Heart; 2011 Sep 26; 97(18):1495-500. PubMed ID: 21700755
    [Abstract] [Full Text] [Related]

  • 17. Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure.
    Yusuf S.
    Herz; 1993 Dec 26; 18 Suppl 1():444-8. PubMed ID: 8125425
    [Abstract] [Full Text] [Related]

  • 18. [Therapeutic value of trimetazidine in patients with coronary heart disease and left ventricular dysfunction].
    Multicentral Collaborative Group on Trimetazidine (Phase IV).
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Sep 26; 33(9):793-5. PubMed ID: 16266453
    [Abstract] [Full Text] [Related]

  • 19. [Influence of therapy schedule on hospitalization frequency and prognosis in heart failure in 3 yrs. observations].
    Sidorowicz K, Tkacz E, Poloński L.
    Pol Merkur Lekarski; 2002 Jan 26; 12(67):30-5. PubMed ID: 11957798
    [Abstract] [Full Text] [Related]

  • 20. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy.
    Tuunanen H, Engblom E, Naum A, Någren K, Scheinin M, Hesse B, Juhani Airaksinen KE, Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J.
    Circulation; 2008 Sep 16; 118(12):1250-8. PubMed ID: 18765391
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.